Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.

@article{Howard2011PharmacodynamicsOE,
  title={Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.},
  author={Susan Julie Howard and Joanne Livermore and Andrew Sharp and Joanne Goodwin and Lea Gregson and Ana Alastruey-Izquierdo and David Scott Perlin and Peter A. Warn and William W Hope},
  journal={Antimicrobial agents and chemotherapy},
  year={2011},
  volume={55 10},
  pages={4880-7}
}
Candida glabrata is a leading cause of disseminated candidiasis. The echinocandins are increasingly used as first-line agents for the treatment of patients with this syndrome, although the optimal regimen for the treatment of invasive Candida glabrata infections in neutropenic patients is not known. We studied the pharmacokinetics (PK) and pharmacodynamics (PD) of micafungin, anidulafungin, and caspofungin in a neutropenic murine model of disseminated Candida glabrata infection to gain further… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy

  • Howard, J S.
  • J. Infect
  • 2011
1 Excerpt

ADAPT 5 user’s guide: pharmacokinetic/pharmacodynamic systems analysis software

  • D. Z. D’Argenio, A. Schumitzky, X. Wang
  • Biomedical Simulations Resource,
  • 2009
2 Excerpts

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America

  • Pappas, G P.
  • Clin. Infect
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…